Pancreatic Neuroendocrine Tumor Clinical Trial
Official title:
Phase I/II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
This research study will test the safety of RAD001 in combination with temozolomide.
- Participants will take RAD001 by mouth daily. They will also take temozolomide by mouth
daily for one week, followed by a one-week break period. This one-week on/one week off
schedule for temozolomide will continue for the duration of the treatment.
- After the first month of treatment, there will be a 7-day observation period during
which no study medication will be taken to observe for any side effects.
- During all treatment cycles (1 cycle is 28 days in length) participants will have a
physical exam and will be asked questions about their general health and specific
questions about any problems they may be experiencing. Initially, participants will come
in every other week. At each of these visits, blood work will be taken to monitor the
participants health.
- After every 2 months of treatment, participants will have a CT scan or MRI done to see
how the medication is working.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05566093 -
EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors
|
N/A | |
Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
Recruiting |
NCT05568017 -
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
|
Phase 2 | |
Not yet recruiting |
NCT06024343 -
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction
|
N/A | |
Recruiting |
NCT03891784 -
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT03204019 -
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
|
Phase 2 | |
Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
Recruiting |
NCT05997056 -
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
|
Phase 2 | |
Not yet recruiting |
NCT06158516 -
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05040360 -
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT05610826 -
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03074513 -
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
|
Phase 2 | |
Completed |
NCT03967951 -
CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
|
||
Completed |
NCT01024387 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Not yet recruiting |
NCT03435770 -
Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms
|
N/A | |
Recruiting |
NCT04134832 -
Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
|
||
Recruiting |
NCT05554744 -
EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors
|
N/A | |
Completed |
NCT02159989 -
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Not yet recruiting |
NCT06406387 -
ATRX/DAXX in EUS-FNB Specimens of Pan-NETs
|